1. Home
  2. Haematology and BMT
  3. Multiple myeloma

Multiple myeloma lenalidomide and dexamethasone oral

Patients with myeloma should be considered for inclusion into clinical trials. Link to ALLG website opens in a new tab or window and ANZCTR website opens in a new tab or window.

Link to Medical Scientific Advisory Group (MSAG) Clinical Practice Guideline Multiple Myeloma opens in a new tab or window

Link to MyeTxScheduler opens in a new tab or window developed by Myeloma Specialist Practice Network of the Haematology Society of Australia and New Zealand Nurses Group

On this page
Expand all Collapse all Back to top

Cycle 1 and further cycles

Drug Dose Route Day
Dexamethasone 40 mg ONCE a week* PO 1, 8, 15, 22
Lenalidomide 25 mg ONCE a day PO 1 to 21

*The eviQ Haematology Reference Committee recommends dexamethasone 20 mg/week starting dose in patients >75 years of ager and dexamethasone 40 mg/week starting dose in patients <75 years of age. Dose reduction based on clinical toxicity and response may be reasonable.rr

Frequency:
28 days 
Cycles:
Continuous until disease progression or unacceptable toxicity.
Notes:

It is the consensus of the eviQ Haematology Reference Committee that consideration should be given to stopping dexamethasone and reducing lenalidomide dose to 10 mg from cycle 9 in newly diagnosed multiple myeloma patients >75 years of age.rr

Drug status:

Dexamethasone is on the PBS general schedule opens in a new tab or window

Lenalidomide: (PBS authority opens in a new tab or window)

NB: patient registration into a pregnancy prevention risk management program is required.

Full prescribing information and Authority Application forms available from the Department of Human Services opens in a new tab or window website

Lenalidomide is available as 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules

Dexamethasone is available as 4 mg and 0.5 mg tablets

Cost:
~ $1,320 per cycle "How this cost is calculated"

The cost displayed on the protocol is intended as rudimentary guide only for the Australian context.

The cost includes anti-cancer drugs only (not antiemetics, supportive medications or consumables), unless otherwise indicated.

Drug unit costs are taken directly from the Pharmaceutical Benefits Scheme (PBS) website (www.pbs.gov.au). These costs are reviewed and updated on eviQ at 6 monthly intervals. Anti-cancer drugs that are not included on the PBS do not have a cost included in eviQ protocols.

Where there are differing unit costs based on vial sizes and tablet strengths, the mean unit cost is used. The cost of oral continuous therapy is based on a 28 day month.

Where oral drugs are available on the PBS for both 30- and 60-day prescriptions, the unit cost for the 30-day supply is used.

The protocol cost is derived from drug dose calculations based upon a default body surface area (BSA) of 1.8 m2; weight of 75 kg; and creatinine clearance of 75 mL/min.

One off loading doses and ongoing maintenance doses are not included in protocol cost calculations.

The cost displayed is the actual drug cost and does not necessarily reflect the cost incurred by the patient as many anti-cancer drugs are reimbursed on the PBS.

The supportive therapies (e.g. antiemetics, premedications, growth factor support etc.), infusion times, diluents, volumes and routes of administration, if included, are listed as defaults. They may vary between institutions and can be substituted to reflect individual institutional policy.

Antiemetics if included in the treatment schedule are based upon recommendations from national and international guidelines. These are defaults only and may be substituted to reflect individual institutional policy. Select here for recommended doses of alternative antiemetics.

Cycle 1 and further cycles

Day 1
Dexamethasone 40 mg (PO) ONCE a week on days 1, 8, 15, and 22. Take in the morning with food.*
Lenalidomide 25 mg (PO) ONCE a day on days 1 to 21. Take at same time each day, either with or without food.
Day 2 to 7
Lenalidomide 25 mg (PO) ONCE a day on days 1 to 21. Take at same time each day, either with or without food.
Day 8
Dexamethasone 40 mg (PO) ONCE a week on days 1, 8, 15, and 22. Take in the morning with food.*
Lenalidomide 25 mg (PO) ONCE a day on days 1 to 21. Take at same time each day, either with or without food.
Day 9 to 14
Lenalidomide 25 mg (PO) ONCE a day on days 1 to 21. Take at same time each day, either with or without food.
Day 15
Dexamethasone 40 mg (PO) ONCE a week on days 1, 8, 15, and 22. Take in the morning with food.*
Lenalidomide 25 mg (PO) ONCE a day on days 1 to 21. Take at same time each day, either with or without food.
Day 16 to 21
Lenalidomide 25 mg (PO) ONCE a day on days 1 to 21. Take at same time each day, either with or without food.
Day 22
Dexamethasone 40 mg (PO) ONCE a week on days 1, 8, 15, and 22. Take in the morning with food.*

*The eviQ Haematology Reference Committee recommends dexamethasone 20 mg/week starting dose in patients >75 years of ager and dexamethasone 40 mg/week starting dose in patients <75 years of age. Dose reduction based on clinical toxicity and response may be reasonable.rr

Note:

It is the consensus of the eviQ Haematology Reference Committee that consideration should be given to stopping dexamethasone and reducing lenalidomide dose to 10 mg from cycle 9 in newly diagnosed multiple myeloma patients >75 years of age.rr

Frequency:
28 days 
Cycles:
Continuous until disease progression or unacceptable toxicity.

Cycle 1 and further cycles

Drug Dose Route Day
Dexamethasone 40 mg ONCE a week* PO 1, 8, 15, 22
Lenalidomide 25 mg ONCE a day PO 1 to 21

*The eviQ Haematology Reference Committee recommends dexamethasone 20 mg/week starting dose in patients >75 years of ager and dexamethasone 40 mg/week starting dose in patients <75 years of age. Dose reduction based on clinical toxicity and response may be reasonable.rr

Frequency:
28 days 
Cycles:
Continuous until disease progression or unacceptable toxicity.
Notes:

It is the consensus of the eviQ Haematology Reference Committee that consideration should be given to stopping dexamethasone and reducing lenalidomide dose to 10 mg from cycle 9 in newly diagnosed multiple myeloma patients >75 years of age.rr

Drug status:

Dexamethasone is on the PBS general schedule opens in a new tab or window

Lenalidomide: (PBS authority opens in a new tab or window)

NB: patient registration into a pregnancy prevention risk management program is required.

Full prescribing information and Authority Application forms available from the Department of Human Services opens in a new tab or window website

Lenalidomide is available as 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules

Dexamethasone is available as 4 mg and 0.5 mg tablets

Cost:
~ $1,320 per cycle "How this cost is calculated"

The cost displayed on the protocol is intended as rudimentary guide only for the Australian context.

The cost includes anti-cancer drugs only (not antiemetics, supportive medications or consumables), unless otherwise indicated.

Drug unit costs are taken directly from the Pharmaceutical Benefits Scheme (PBS) website (www.pbs.gov.au). These costs are reviewed and updated on eviQ at 6 monthly intervals. Anti-cancer drugs that are not included on the PBS do not have a cost included in eviQ protocols.

Where there are differing unit costs based on vial sizes and tablet strengths, the mean unit cost is used. The cost of oral continuous therapy is based on a 28 day month.

Where oral drugs are available on the PBS for both 30- and 60-day prescriptions, the unit cost for the 30-day supply is used.

The protocol cost is derived from drug dose calculations based upon a default body surface area (BSA) of 1.8 m2; weight of 75 kg; and creatinine clearance of 75 mL/min.

One off loading doses and ongoing maintenance doses are not included in protocol cost calculations.

The cost displayed is the actual drug cost and does not necessarily reflect the cost incurred by the patient as many anti-cancer drugs are reimbursed on the PBS.

The supportive therapies (e.g. antiemetics, premedications, growth factor support etc.), infusion times, diluents, volumes and routes of administration, if included, are listed as defaults. They may vary between institutions and can be substituted to reflect individual institutional policy.

Antiemetics if included in the treatment schedule are based upon recommendations from national and international guidelines. These are defaults only and may be substituted to reflect individual institutional policy. Select here for recommended doses of alternative antiemetics.

Cycle 1 and further cycles

Day 1
Dexamethasone 40 mg (PO) ONCE a week on days 1, 8, 15, and 22. Take in the morning with food.*
Lenalidomide 25 mg (PO) ONCE a day on days 1 to 21. Take at same time each day, either with or without food.
Day 2 to 7
Lenalidomide 25 mg (PO) ONCE a day on days 1 to 21. Take at same time each day, either with or without food.
Day 8
Dexamethasone 40 mg (PO) ONCE a week on days 1, 8, 15, and 22. Take in the morning with food.*
Lenalidomide 25 mg (PO) ONCE a day on days 1 to 21. Take at same time each day, either with or without food.
Day 9 to 14
Lenalidomide 25 mg (PO) ONCE a day on days 1 to 21. Take at same time each day, either with or without food.
Day 15
Dexamethasone 40 mg (PO) ONCE a week on days 1, 8, 15, and 22. Take in the morning with food.*
Lenalidomide 25 mg (PO) ONCE a day on days 1 to 21. Take at same time each day, either with or without food.
Day 16 to 21
Lenalidomide 25 mg (PO) ONCE a day on days 1 to 21. Take at same time each day, either with or without food.
Day 22
Dexamethasone 40 mg (PO) ONCE a week on days 1, 8, 15, and 22. Take in the morning with food.*

*The eviQ Haematology Reference Committee recommends dexamethasone 20 mg/week starting dose in patients >75 years of ager and dexamethasone 40 mg/week starting dose in patients <75 years of age. Dose reduction based on clinical toxicity and response may be reasonable.rr

Note:

It is the consensus of the eviQ Haematology Reference Committee that consideration should be given to stopping dexamethasone and reducing lenalidomide dose to 10 mg from cycle 9 in newly diagnosed multiple myeloma patients >75 years of age.rr

Frequency:
28 days 
Cycles:
Continuous until disease progression or unacceptable toxicity.
  • Relapsed/refractory multiple myeloma (after failure of at least one prior therapy)
  • Newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.
Caution with oral anti-cancer drugs

Select links for information on the safe prescribing, dispensing and administration of orally administered anti-cancer drugs. 

Read more about at COSA guidelines for the safe prescribing, dispensing and administration of systemic cancer therapy opens in a new tab or window and oral anti-cancer therapy opens in a new tab or window
Emetogenicity minimal or low

No routine prophylaxis required. If patients experience nausea and/or vomiting, consider using the low emetogenic risk regimen.

Read more about preventing anti-cancer therapy induced nausea and vomiting
Teratogenic effects

Immunomodulatory drugs (IMiDs) include thalidomide, lenalidomide and pomalidomide. They can cause severe congenital disabilities or death to an unborn baby when taken during pregnancy.  

All patients and partners of patients that can conceive a child must use at least one reliable contraceptive method for at least 4 weeks before starting treatment, during treatment (including dose interruptions), and for 4 weeks after stopping treatment. 
Male patients should also use a condom when having sexual intercourse with a woman of childbearing potential during treatment (including dose interruptions), and for 4 weeks after stopping treatment.
In female patients and female partners of male patients, a pregnancy test should be carried out prior to initiating treatment (after 4 weeks of contraception use), weekly during the first month of treatment and monthly thereafter.
Effective contraception methods and adequate contraception timeframes should be discussed with all patients of reproductive potential.
Prescription of an IMiD requires patient registration with a pregnancy prevention program.

Full prescribing information and Authority Application forms available from the Department of Human Services website opens in a new tab or window
Thromboembolism

Patients are at an increased risk of venous thrombosis with this treatment. 

Risk assessment for VTE should be performed prior to and during treatment. 

It is the consensus opinion of the Haematology Reference Committee that concomitant thromboprophylaxis is recommended: consider using low dose aspirin for patients without pre-existing risk factors, while patients with pre-existing risk factors should receive enoxaparin 40 mg subcut daily for the duration of treatment (unless contraindicated; reduce dose in kidney dysfunction).

Read more about the prophylaxis of venous thromboembolism (VTE) in multiple myeloma
Bone modifying agents

Use of a bone modifying agent (BMA) should be considered in all patients with symptomatic myeloma requiring treatment. For patients with newly diagnosed symptomatic myeloma, zoledronic acid, pamidronate or denosumab should be considered for monthly administration (adjust for kidney dysfunction where appropriate) for up to 2 years. A longer duration of therapy may be appropriate (MRC M IX trial).r

For more information, please see the following protocols:
ID 137 Multiple myeloma zoledronic acid
ID 147 Multiple myeloma pamidronate
ID 3964 Multiple myeloma denosumab - note denosumab is TGA approved but not PBS reimbursed for this indication.
Bisphosphonates and dental review

Caution should be taken with prolonged use of bisphosphonates due to the risk of osteonecrosis of the jaw (ONJ). A dental review prior to treatment is recommended, and all dental issues treated before the initiation of bisphosphonates. Dental review 6 to 12 monthly during treatment is advisable to minimise risk of ONJ. Concurrent daily oral supplements of calcium 500 mg and vitamin D 400 International Units are recommended.

Read more about medication-related osteonecrosis of the jaw (MRONJ)
Corticosteroids

Diabetic patients should monitor their blood glucose levels closely. To minimise gastric irritation, advise patient to take immediately after food. Consider the use of a H2 antagonist or proton pump inhibitor if appropriate.

Read more about acute short term effects from corticosteroids
Tumour lysis risk

Assess patient for risk of developing tumour lysis syndrome.

Read more about prevention and management of tumour lysis syndrome.
Pneumocystis jirovecii pneumonia (PJP) prophylaxis

PJP prophylaxis is recommended e.g. trimethoprim/sulfamethoxazole 160/800 mg PO one tablet twice daily, twice weekly (e.g. on Mondays and Thursdays) OR one tablet three times weekly (e.g. on Mondays, Wednesdays and Fridays).

Read more about prophylaxis of pneumocystis jiroveci (carinii) in cancer patients
Antiviral prophylaxis

­

Read more about antiviral prophylaxis drugs and doses
Growth factor support

G-CSF (short or long-acting) is available on the PBS for chemotherapy induced neutropenia depending on clinical indication and/or febrile neutropenia risk.  

Access the PBS website opens in a new tab or window
Blood tests

FBC, EUC, eGFR, LFTs, calcium, magnesium, phosphate and BSL at baseline then monthly thereafter.
Patients with normal pre-treatment FBC: repeat FBC fortnightly for the first four weeks then monthly thereafter.
Patients with pre-treatment cytopenias: repeat FBC 1 to 2 weekly for the first four weeks then monthly thereafter.

Consider monitoring thyroid function tests (reported cases of hypothyroidism).
Hepatitis B screening and prophylaxis

Routine screening for HBsAg and anti-HBc is recommended prior to initiation of treatment. Prophylaxis should be determined according to individual institutional policy.

Read more about hepatitis B screening and prophylaxis in cancer patients requiring cytotoxic and/or immunosuppressive therapy
Vaccinations

Live vaccines are contraindicated in cancer patients receiving immunosuppressive therapy and/or who have poorly controlled malignant disease. Possible suboptimal response to inactivated vaccines.

For more information about vaccinations in people with cancer refer to the Australian Immunisation Handbook opens in a new tab or window.
Fertility and lactation

Cancer treatment can have harmful effects on fertility and this should be discussed with all patients of reproductive potential prior to commencing treatment.

Possibility of infant risk should be discussed with breastfeeding patients.

Read more about the impact of cancer treatment on fertility opens in a new tab or window
Evidence for dose modifications is limited, and the recommendations made on eviQ are intended as a guide only. They are generally conservative with an emphasis on safety. Any dose modification should be based on clinical judgement, and the individual patient’s situation including but not limited to treatment intent (curative vs palliative), the anti-cancer regimen (single versus combination therapy versus chemotherapy versus immunotherapy), biology of the cancer (site, size, mutations, metastases), other treatment related side effects, additional co-morbidities, performance status and patient preferences.Suggested dose modifications are based on clinical trial findings, product information, published guidelines and reference committee consensus . The dose reduction applies to each individual dose and not to the total number of days or duration of treatment cycle unless stated otherwise. Non-haematological gradings are based on Common Terminology Criteria for Adverse Events (CTCAE) opens in a new tab or window unless otherwise specified. Renal and hepatic dose modifications have been standardised where possible. For more information see dosing considerations & disclaimer.

Lenalidomide:

  • Initial treatment with lenalidomide should not be started if ANC less than 1.0 x 109/L and/or platelets less than 75 x 109/L (or platelets less than 30 x 109/L if heavy bone marrow involvement), however, may be commenced at the discretion of the treating haematologist.
Dose reduction steps for lenalidomide to manage haematological toxicities
  Newly diagnosed multiple myeloma transplant ineligible Previously treated multiple myeloma
Starting dose 25 mg 25 mg
Dose level 1 20 mg 15 mg
Dose level 2 15 mg 10 mg
Dose level 3 10 mg 5 mg
Dose level 4 5 mg  
Haematological toxicity
ANC x 109/L (pre-treatment blood test)
First fall to less than 0.5 Interrupt lenalidomide treatment
Return to greater than or equal to 0.5 when neutropenia is the only observed toxicity Resume lenalidomide at starting dose
Return to greater than or equal to 0.5 when dose-dependent haematological toxicities other than neutropenia are observed Resume lenalidomide at dose level 1
For each subsequent drop less than 0.5 Interrupt lenalidomide treatment
Return to greater than or equal to 0.5 Resume lenalidomide at next lower dose level (dose level 2 or 3)
Do not dose below 5 mg
Consider using G-CSF opens in a new tab or window for neutropenia
Platelets x 109/L (pre-treatment blood test)
First fall to less than 30 Interrupt lenalidomide treatment
Return to greater than or equal to 30 Resume lenalidomide at dose level 1
For each subsequent drop less than 30 Interrupt lenalidomide treatment
Return to greater than or equal to 30 Resume lenalidomide at next lower dose level (dose level 2 or 3)
Do not dose below 5 mg
Kidney dosing recommendations 
  • Suggested dose modifications are based on the International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD).
  • Where one or more drugs in a protocol is recommended to be avoided, consider using a clinically appropriate alternative treatment protocol instead.
  • Before dose adjusting or omitting a drug, consider treatment intent.
  • In kidney replacement therapy consult a multidisciplinary team consisting of oncology/haematology with nephrology and/or clinical pharmacology for the management of dosing. 
  • For complete information on individual drug recommendations please review the individual drug monograph in the ADDIKD guideline.
  • Lenalidomide - after initial dose adjustment, there should be a continuous process of dose adjustment considering variations in kidney function during treatment and drug tolerance. The dose may be escalated to 15 mg once daily after 2 cycles if the patient is not responding to treatment and is tolerating treatment.
eGFR
(mL/min/1.73m2)		 Lenalidomide* Dexamethasone**
≥ 60

Full dose

No dose reduction required in kidney dysfunction.

 

 

 

 

 

 

 

 

 

 

 

 
45 - 59

Reduce to 10 mg daily

Increased risk of adverse events
30 - 44

Reduce to 10 mg daily

Increased risk of adverse events
15 - 29

Reduce to 15 mg every 48 hours

Increased risk of adverse events
< 15
(without kidney replacement therapy)

Reduce to 15 mg every 48 hours

Increased risk of adverse events
Kidney replacement therapy^

Reduce to 5 mg daily post dialysis^

Increased risk of adverse events

* The dose reduction applies to each individual dose and not to the total number of days or duration of lenalidomide per treatment cycle.

** This drug was not included in the ADDIKD guideline.

^ Dialysis dosing recommendation as per the lenalidomide product information and included as per the RCM.
Hepatic impairment
No formal studies of lenalidomide in patients with hepatic impairment, therefore no specific dose recommendations.
Dermatological reactionsrr
Rare cases of Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported. These may be potentially fatal.
Rash  
Grade 1 Continue lenalidomide. Treat with topical corticosteroids and oral antihistamines.
Grade 2 Consider interruption of lenalidomide. Treat with topical corticosteroids and oral antihistamines until toxicity resolves.
Grade 3 Consider interruption of lenalidomide. Treat with oral antihistamines or oral corticosteroids until toxicity resolves.
Stevens-Johnson syndrome or toxic epidermal necrolysis Permanent discontinuation of lenalidomide treatment. 
Dexamethasone and lenalidomide
The reference committee recommend that the dexamethasone and lenalidomide dose be individualised or dose reduced where the high dose regimen is not well tolerated (i.e. in older patients or those that develop severe steroid related side effects).

The drug interactions shown below are not an exhaustive list. For a more comprehensive list and for detailed information on specific drug interactions and clinical management, please refer to the specific drug product information and the following key resources:  

For more information see References & Disclaimer.

Dexamethasone
  Interaction Clinical management
CYP3A4 interactions Dexamethasone is a substrate of CYP3A4 and a weak to moderate inducer of CYP3A4. The clinical relevance of CYP3A4 induction by dexamethasone is unknown as the mechanism has yet to be established The effects of the concomitant use of dexamethasone with other CYP3A4 inducers, inhibitors or substrates is variable. If used concomitantly, monitor patients closely for adverse drug reactions
Warfarin Concurrent use may result in increased risk of bleeding or diminished effects of warfarin Monitor prothrombin time / INR (especially during initiation or discontinuation) and for signs of drug toxicity during concomitant use; adjust warfarin dose as required
Oral hypoglycaemics Corticosteroids may cause hyperglycaemia and worsen diabetes control Monitor blood glucose levels and adjust oral hypoglycaemic dose as required
Lenalidomide
  Interaction Clinical management
Digoxin Potentially increased digoxin plasma levels when combined with lenalidomide; mechanism unknown Monitor digoxin levels and for signs of drug toxicity during treatment with lenalidomide
Nephrotoxic drugs (e.g. aminoglycosides, amphotericin, contrast dye, frusemide, NSAIDs) Additive nephrotoxicity Avoid combination or monitor kidney function closely
HMG-CoA reductase inhibitors (Statins) Potentially additive toxicity Monitor for signs and symptoms of myotoxicity and rhabdomyolysis (e.g.: unexplained muscle pain, muscle stiffness or tenderness, dark urine) during concomitant use
Erythropoietic agents, combined oral contraceptives or hormone replacement therapy Additive risk of thromboembolic events due to an increased risk of VTE Consider the benefit/risk of concomitant therapy
Immunosuppressants (e.g. abatacept and baricitinib etc.) Increased risk of infection Concurrent use not recommended. If an immunosuppressant must be used, monitor closely for signs of infection
Bile acid sequestrants (e.g. colestyramine) Potentially reduced lenalidomide absorption when taken at the same time Administer lenalidomide 1 hour before or 4-6 hours after colestyramine
General
  Interaction Clinical management
Warfarin Anti-cancer drugs may alter the anticoagulant effect of warfarin. Monitor INR regularly and adjust warfarin dosage as appropriate; consider alternative anticoagulant.
Direct oral anticoagulants (DOACs) e.g. apixaban, rivaroxaban, dabigatran

Interaction with both CYP3A4 and P-gp inhibitors /inducers.

DOAC and anti-cancer drug levels may both be altered, possibly leading to loss of efficacy or toxicity (i.e. increased bleeding).

Apixaban: avoid concurrent use with strong CYP3A4 opens in a new tab or window and P‑gp opens in a new tab or window inhibitors. If treating VTE, avoid use with strong CYP3A4 opens in a new tab or window and P‑gp opens in a new tab or window inducers. 

Rivaroxaban: avoid concurrent use with strong CYP3A4 opens in a new tab or window and P‑gp opens in a new tab or window  inhibitors.

Dabigatran: avoid combination with strong P‑gp opens in a new tab or window inducers and inhibitors.

If concurrent use is unavoidable, monitor closely for efficacy/toxicity of both drugs.
Digoxin Anti-cancer drugs can damage the lining of the intestine; affecting the absorption of digoxin. Monitor digoxin serum levels; adjust digoxin dosage as appropriate.
Antiepileptics Both altered antiepileptic and anti-cancer drug levels may occur, possibly leading to loss of efficacy or toxicity. Where concurrent use of an enzyme-inducing antiepileptic cannot be avoided, monitor antiepileptic serum levels for toxicity, as well as seizure frequency for efficacy; adjust dosage as appropriate.
Also monitor closely for efficacy of the anti-cancer therapy.
Antiplatelet agents and NSAIDs Increased risk of bleeding due to treatment related thrombocytopenia. Avoid or minimise combination.
If combination deemed essential, (e.g. low dose aspirin for ischaemic heart disease) monitor for signs of bleeding.
Serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs e.g. paroxetine) and serotonin noradrenaline reuptake inhibitors (SNRIs e.g. venlafaxine) Increased risk of serotonin syndrome with concurrent use of 5-HT3 receptor antagonists (e.g. palonosetron, ondansetron, granisetron, tropisetron, dolasetron, etc.) Avoid combination.
If combination is clinically warranted, monitor for signs and symptoms of serotonin syndrome (e.g. confusion, agitation, tachycardia, hyperreflexia).
For more information link to TGA Medicines Safety Update opens in a new tab or window

eviQ provides safe and effective instructions on how to administer cancer treatments. However, eviQ does not provide every treatment delivery option, and is unable to provide a comprehensive list of cancer treatment agents and their required IV line giving set/filter or address chemical compatibilities related to IV drug preparation and administration. There may be alternative methods of treatment administration, and alternative supportive treatments that are also appropriate. Please refer to the individual product information monographs via the TGA opens in a new tab or window and Australian Injectable Drugs Handbook opens in a new tab or window websites for further information.

eviQ is currently updating the way information is presented in the administration section, if you notice any discrepancies please let us know, via feedback@eviq.org.au.

Day 1

This is an oral treatment

Pre treatment assessment

Any toxicity grade 2 or greater may require dose reduction, delay or omission of treatment and review by medical officer before commencing treatment.

Anti-cancer drug patient assessment tool prior to each day of treatment.

Dexamethasone

Administer dexamethasone:
  • administer orally ONCE a week in the morning, on days 1, 8, 15 and 22 
  • with or immediately after food.

Note: if a dose is forgotten or vomited, contact treating team.

Lenalidomide

Administer lenalidomide:
  • orally ONCE a day, at the same time each day, on days 1 to 21 every 28 days
  • to be swallowed whole with a glass of water; do not break, crush or chew
  • can be taken either with or without food.

Note: missed doses should not be taken if it is less than 12 hours until the next dose.

Post administration

Continue safe handling precautions (reproductive risk only) for 7 days after completion of drug(s).

Days 2 to 7

This is an oral treatment

Pre treatment assessment

Any toxicity grade 2 or greater may require dose reduction, delay or omission of treatment and review by medical officer before commencing treatment.

Anti-cancer drug patient assessment tool prior to each day of treatment.

Lenalidomide

Administer lenalidomide:
  • orally ONCE a day, at the same time each day, on days 1 to 21 every 28 days
  • to be swallowed whole with a glass of water; do not break, crush or chew
  • can be taken either with or without food.

Note: missed doses should not be taken if it is less than 12 hours until the next dose.

Post administration

Continue safe handling precautions (reproductive risk only) for 7 days after completion of drug(s).

Day 8

This is an oral treatment

Pre treatment assessment

Any toxicity grade 2 or greater may require dose reduction, delay or omission of treatment and review by medical officer before commencing treatment.

Anti-cancer drug patient assessment tool prior to each day of treatment.

Dexamethasone

Administer dexamethasone:
  • administer orally ONCE a week in the morning, on days 1, 8, 15 and 22 
  • with or immediately after food.

Note: if a dose is forgotten or vomited, contact treating team.

Lenalidomide

Administer lenalidomide:
  • orally ONCE a day, at the same time each day, on days 1 to 21 every 28 days
  • to be swallowed whole with a glass of water; do not break, crush or chew
  • can be taken either with or without food.

Note: missed doses should not be taken if it is less than 12 hours until the next dose.

Post administration

Continue safe handling precautions (reproductive risk only) for 7 days after completion of drug(s).

Days 9 to 14

This is an oral treatment

Pre treatment assessment

Any toxicity grade 2 or greater may require dose reduction, delay or omission of treatment and review by medical officer before commencing treatment.

Anti-cancer drug patient assessment tool prior to each day of treatment.

Lenalidomide

Administer lenalidomide:
  • orally ONCE a day, at the same time each day, on days 1 to 21 every 28 days
  • to be swallowed whole with a glass of water; do not break, crush or chew
  • can be taken either with or without food.

Note: missed doses should not be taken if it is less than 12 hours until the next dose.

Post administration

Continue safe handling precautions (reproductive risk only) for 7 days after completion of drug(s).

Day 15

This is an oral treatment

Pre treatment assessment

Any toxicity grade 2 or greater may require dose reduction, delay or omission of treatment and review by medical officer before commencing treatment.

Anti-cancer drug patient assessment tool prior to each day of treatment.

Dexamethasone

Administer dexamethasone:
  • administer orally ONCE a week in the morning, on days 1, 8, 15 and 22 
  • with or immediately after food.

Note: if a dose is forgotten or vomited, contact treating team.

Lenalidomide

Administer lenalidomide:
  • orally ONCE a day, at the same time each day, on days 1 to 21 every 28 days
  • to be swallowed whole with a glass of water; do not break, crush or chew
  • can be taken either with or without food.

Note: missed doses should not be taken if it is less than 12 hours until the next dose.

Post administration

Continue safe handling precautions (reproductive risk only) for 7 days after completion of drug(s).

Days 16 to 21

This is an oral treatment

Pre treatment assessment

Any toxicity grade 2 or greater may require dose reduction, delay or omission of treatment and review by medical officer before commencing treatment.

Anti-cancer drug patient assessment tool prior to each day of treatment.

Lenalidomide

Administer lenalidomide:
  • orally ONCE a day, at the same time each day, on days 1 to 21 every 28 days
  • to be swallowed whole with a glass of water; do not break, crush or chew
  • can be taken either with or without food.

Note: missed doses should not be taken if it is less than 12 hours until the next dose.

Post administration

Continue safe handling precautions (reproductive risk only) for 7 days after completion of drug(s).

Day 22

This is an oral treatment

Dexamethasone

Administer dexamethasone:
  • administer orally ONCE a week in the morning, on days 1, 8, 15 and 22 
  • with or immediately after food.

Note: if a dose is forgotten or vomited, contact treating team.

Post administration

Continue safe handling precautions (reproductive risk only) for 7 days after completion of drug(s).

Discharge information

Discharge medications

Dexamethasone tablets and lenalidomide capsules - with written instructions on how to take them.

Antiemetics - as/if prescribed.

Thromboprophylaxis - low dose aspirin OR enoxaparin 40 mg subcut daily for the duration of treatment, if prescribed.

Growth factor support - as/if prescribed, and arrangements for administration.

Prophylaxis medications - as/if prescribed, i.e. antivirals, PJP prophylaxis, tumour lysis prophylaxis and medication for constipation.

Patient information

Ensure patient receives protocol patient information sheet.

The side effects listed below are not a complete list of all possible side effects for this treatment. Side effects are categorised into the approximate onset of presentation and should only be used as a guide.

Immediate (onset hours to days)
Flu-like symptoms
Taste and smell alteration

Read more about taste and smell changes

Early (onset days to weeks)
Neutropenia

Abnormally low levels of neutrophils in the blood. This increases the risk of infection. Any fever or suspicion of infection should be investigated immediately and managed aggressively. 

Read more about immediate management of neutropenic fever
Thrombocytopenia

A reduction in the normal levels of functional platelets, increasing the risk of abnormal bleeding.  

Read more about thrombocytopenia
Arthralgia and myalgia

Generalised joint pain or and/or stiffness and muscle aches, often worse upon waking or after long periods of inactivity. Can improve with movement. May be mild or severe, intermittent or constant and accompanied by inflammation. 

Read more about arthralgia and myalgia
Constipation
Cough
Diarrhoea

Read more about treatment induced diarrhoea
Fatigue

Read more about fatigue
Respiratory tract infection
Skin rash

Anti-cancer drugs can cause a number of changes in the skin with maculo-papular rash the most common type of drug-induced skin reaction. 

Read more about skin rash
Side effects of corticosteroids

Insomnia, oedema, increased risk of infection e.g. oral thrush, gastric irritation, worsening of peptic ulcer disease, increased blood sugar levels, loss of diabetic control, mood and behavioural changes - including anxiety, euphoria, depression, mood swings, increased appetite and weight gain, osteoporosis and fractures (long term use), bruising and skin fragility are associated with corticosteroid use.
Thromboembolism

Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE) is significantly increased in multiple myeloma patients treated with thalidomide in combination with other therapies including doxorubicin, melphalan and prednisolone or dexamethasone; and lenalidomide and pomalidomide in combination with dexamethasone.

Read more about management of thromboembolism (VTE) in multiple myeloma

Late (onset weeks to months)
Anaemia

Abnormally low levels of red blood cells (RBCs) or haemoglobin in the blood. 

Read more about anaemia
Diarrhoea (late onset)

Chronic loose stools due to bile acid malabsorption has been observed in patients receiving lenalidomide. Referral to Gastroenterology should be considered. An empiric trial of cholestyramine (a bile-acid binding resin) is reasonable for these patients.

Read more about treatment induced diarrhoea
Hypothyroidism
Muscle cramps

Cramping in the hands, calves and/or thighs associated with hypomagnesaemia (low magnesium) and/or hypocalcaemia (low calcium). 
Stevens-Johnson syndrome (SJS)

Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) is characterised by fever, malaise, a painful rash, erythematous macules, targetoid lesions, or diffuse erythema progressing to vesicles and bullae, and oral, ocular and/or genital mucositis with painful mucosal erosion. Patients who develop SJS/TEN should never be re-exposed to the causative agent.

Delayed (onset months to years)
Cataract

A disorder characterised by partial or complete opacity of the crystalline lens of one or both eyes. This results in a decrease in visual acuity and eventual blindness if untreated. 
Secondary malignancies

This regimen has a role in both the upfront and relapsed/refractory settings for the treatment of multiple myeloma.

The FIRST trial (MM-020) provided supporting evidence for the use of lenalidomide/dexamethasone (LenDex or Rd) in the upfront setting for transplant-ineligible patients.r Between 2008 and 2011 across 18 countries and multiple treatment centres, a total of 1,623 patients were assigned in 1:1:1 randomisation to receive either LenDex in 28-day cycles till disease progression (Rd continuous), LenDex for 18 cycles then stop (Rd18), or melphalan/prednisone/thalidomide (MPT) every 42 days for 12 cycles. Continuous Rd was found to achieve better median progression-free survival (PFS) and trend towards better overall survival (OS) compared to the other two comparator regimens. Amongst the previously treated patients, the studies supporting the use of this regimen were published as MM-009 4 and MM-0105, with longer-term follow-up published in 2009.r

In paired randomised studies recruiting in the USA (MM-009), Europe, Israel and Australia (MM-010), lenalidomide with dexamethasone was compared to dexamethasone alone. These studies were double-blind, placebo-controlled, multicentre studies. Eligible patients had progressive myeloma after at least 1 line of therapy and had measurable disease not progressing on a regimen including high-dose dexamethasone. Other important eligibility criteria included ECOG = 2, ALT/AST <3 x ULN, total bilirubin <2 x ULN, creatinine <221 micromol/L, ANC >1.0 x 109/L, and platelet count >75 x 109/L (>30 x 109/L if heavy marrow infiltration). Treatment assignment was stratified according to B-2 microglobulin, prior SCT, and number of prior therapies. The primary endpoint was time to disease progression.rr

Efficacy

Figure 1: Kaplan–Meier Estimates of Progression-free Survival, Overall Survival, and Duration of Response from the FIRST trial (MM-020)r.

Panel A shows the estimated median progression-free survival in the intention-to-treat population. Panel B shows the estimated overall survival in the intention to treat population. Panel C shows the estimated median duration of response in patients with a partial response or better. In all panels, the horizontal line indicates the median, and short vertical lines on each curve indicate patients with censored data. Ld denotes lenalidomide–dexamethasone, Ld18 18 cycles of lenalidomide–dexamethasone, and MPT melphalan– prednisone–thalidomide.
© The New England Journal of Medicine 2014

In MM-009,r 177 patients were assigned to the lenalidomide/dexamethasone group and 176 to the dexamethasone group. Complete, near-complete, or partial responses occurred in 108 patients (61.0%) in the lenalidomide group and in 35 patients (19.9%) in the placebo group (P<0.001); complete responses occurred in 14.1% and 0.6%, respectively (P<0.001). The median time to progression was 11.1 months in the lenalidomide group and 4.7 months in the placebo group (P<0.001). Median OS times in the two groups were 29.6 months and 20.2 months, respectively (P<0.001). In MM-010,r 176 patients were assigned to the lenalidomide/dexamethasone group and 175 to the dexamethasone group. Complete, near-complete, or partial responses occurred in 106 patients (60.2%) in the lenalidomide group and in 42 patients (24%) in the placebo group (P<0.001); complete responses occurred in 15.9% and 3.4%, respectively (P<0.001). The median time to progression was 11.3 months in the lenalidomide group and 4.7 months in the placebo group (P<0.001). OS was significantly improved in the lenalidomide group (hazard ratio for death, 0.66; P = 0.03). A pooled analysis with longer follow-up (median 48 months) confirmed lenalidomide/dexamethasone significantly improved overall response (60.6 vs. 21.9%, p<0.001), complete response rate (15.0 vs. 2.0%, p<0.001), time to progression (median 13.4 vs. 4.6 months, p<0.001), duration of response (median of 15.8 vs. 7 months, p<0.001), and OS (median 38.0 vs. 31.6 months, p=0.045).r A further analysis suggests this efficacy is maintained in patients aged over 65 years.r A small non-randomised study of 45 patients aged over 75 years with relapsed myeloma found 62% overall response rate and median PFS of 14 months, similar to the MM-009 and MM-010 studies.r

Lastly, most studies have utilised a high-dose dexamethasone regimen of 40 mg on days 1 to 4, 9 to 12 and 17 to 20 in the first four 28-day cycles with 40 mg on days 1 to 4 in subsequent cycles. Rajkumar et al.r compared this high-dose dexamethasone regimen with 40 mg on days 1, 8, 15 and 22 of every 28-day cycle during the first 4 cycles in patients with newly diagnosed myeloma prior to ASCT. The study was stopped after the second interim analysis with 50% of patients completing the study and a median follow-up of 1 year as OS (a secondary endpoint) was significantly greater in the low-dose dexamethasone cohort (96% vs 87% OS, p=0·0002). Grade 3 or higher toxicity (52% vs 35% p=0.0001), deaths (12 vs 1, p=0.003), venous thromboembolism (26% vs 12% p=0.0003) and infection (16% vs 9% p=0.04) were significantly more frequent in the high-dose dexamethasone cohort. Given this and other experience with the high-dose dexamethasone regimens, the reference committee recommend that the dexamethasone dose be individualised or dose reduced where the high-dose regimen is not well tolerated (i.e. in older patients or those that develop severe steroid-related side effects).

Table 1: Response rates, TTP, PFS and OS: Pooled Analysis of MM-009 and MM-010 Trials:r

© Leukemia 2009

Toxicity

In the combined analysis,r grade 3 or 4 adverse events were reported in 83.3% of the lenalidomide/dexamethasone group and in 69.7% of the dexamethasone group. The grade 3 or 4 events resulted in study discontinuation in 19.8% and 10.2% of patients. Grade 3 or 4 adverse events occurring in >5% of patients are summarised in the table below. The main differences were increased bone marrow suppression (neutropenia, thrombocytopenia and anaemia) and thromboembolism with the combination of lenalidomide and dexamethasone compared with dexamethasone alone. Hyperglycaemia was seen in almost 8% of patients. The most frequently reported non-haematologic adverse effects included fatigue, insomnia, dizziness, diarrhoea, constipation, muscle cramps and infection. Infection was observed twice as often in the lenalidomide/dexamethasone cohort (Grade 3 or 4 ~21% vs 12%, p=0.14). The reference committee recommends routine antimicrobial and thromboprophylaxis.

A retrospective analysis of phase III data has shown that lenalidomide/dexamethasone remains effective and well-tolerated in patients with moderate or severe renal impairment (RI), albeit with an increase in myelosuppression.r Lenalidomide has a predominantly renal route of excretion and in patients with RI the plasma concentration and half-life of the drug are significantly increased. As a consequence, lower starting doses are required in patients with RI to avoid over-exposure and an increased risk of adverse events, while maintaining good therapeutic index.

After > 60 months follow-up of the FIRST trial cohort of patients, there were no new safety signals compared to earlier studies. The rate of grade 3-4 infections were observed in a greater proportion of Rd continuous patients (32%), compared to Rd18 (22%) or MPT (17%). The rate of second primary solid tumours was equivalent in the subgroups, with slightly higher haematological malignancies in the MPT cohort (3%, compared to Rd continuous 1% and Rd18 <1%).r

Table 2: Grade 3 and 4 Adverse Events: 'First' Trialr

© The New England Journal of Medicine 2014

Figure 2: Grade 3 and 4 Adverse Events: Pooled Analysis of MM-009 and MM-010 Trials:r

© Leukemia 2009

[%id%]
[%title%]

Flinders Filters has partnered with eviQ to build reliable, robust search filters to retrieve core high level evidence on topics of significance to eviQ. The project goal is the provision of a sustainable model for evidence retrieval to ensure ongoing currency of content.

These search filters have been developed to retrieve the most up to date evidence from PubMed, in real time, using specifically designed search filters built to meet our needs.

Searches can be used when a protocol is scheduled for review or at any time you choose. Please click on the Specific, Balanced and Sensitive tabs below to access the Pubmed searches.

Specific opens in a new tab or window Balanced opens in a new tab or window Sensitive opens in a new tab or window
restricted to retrieving randomised control trials and systematic reviews.

is the middle ground between sensitive and specific searches.

retrieves all clinically relevant evidence - generally a broader search on a given topic.

Access Flinders Filters opens in a new tab or window, a division of the Flinders Digital Health Research Centre at Flinders University to read more about research solutions to searching problems.

Troubleshooting

Occasionally the searches may not display correctly or take too long to load (and will eventually timeout). This may be caused by Internet Explorer being unable to handle long URL's. You can rectify this by using Firefox, Safari or Google chrome. It is always a good idea to clear the cache regularly to ensure you are getting the most up to date search.

Feedback

If you identify any new articles that you believe should be included in the content, please use the feedback button below to inform us of the name of the article(s). 

Version 8

Date Summary of changes
21/03/2024 Lenalidomide dose reduction steps updated to align with product information. Version number changed to V.8.

Version 7

Date Summary of changes
10/08/2023

Protocol updated with ADDIKD guideline recommendations. New kidney dosing recommendation table added to dose modification section.

PDF of previous protocol.

Version number changed to V.7.
12/12/2023

Protocol reviewed by the Haematology Reference Committee on the 13/10/2023. The following updates were made:

  • note under treatment schedule added regarding cessation of dexamethasone and reduction of lenalidamide dose to 10 mg from cycle 9 in patients >75 as per Bringhen et al. 2010
  • note "In the MM09 and MM010 studies, the main dose limiting toxicities of lenalidomide were neutropenia and thrombocytopenia, manageable with dose adjustment and/or addition of growth factor support; and venous thromboembolic events managed with anticoagulants" removed as this information exists in the evidence section
  • minor formatting update

Review in 4 years

Version 6

Date Summary of changes
13/04/2023

Reviewed at the 2022 eviQ Haematology Reference Committee meeting with the following changes:

  • Note regarding dexamethasone reduction in specific patient populations added to treatment schedule notes
  • Bone modifying agents block added to clinical information, related note removed from treatment schedule and linked pages removed
  • Link to Medical Scientific Advisory Group (MSAG) guidelines updated
  • Changed all references of ‘i-AccessTM program’ to ‘pregnancy prevention risk management program’
  • Lenalidomide administration details updated in treatment schedule, administration and patient information

Other changes include:

  • Specific medications removed from G-CSF note in 'Dose modifications' section
  • Dose modifications for rash updated to align with product information
  • Cataract, cough and respiratory tract infection added to side effects

Changed to v.6. Review in 2 years.

Version 5

Date Summary of changes
19/03/2010 New eviQ protocol presented at Haematology Reference Group meeting.
20/05/2010 Approved and published on eviQ.
02/08/2010 Updated PCP prophylaxis recommendations.
20/01/2012 PHC view added.
19/02/2012 New format to allow for export of protocol information.
Protocol version number changed to v.2.
Antiemetics and premedication added to the treatment schedule.
Additional Clinical Information, Key Prescribing table and Key Administration table combined into new section titled Clinical Considerations.
Drug specific information placed behind the drug name link.
30/03/2012 Lenalidomide has been reclassified from minimal to low emetic potential to align with MASCC Antiemetic Guideline 2011.
31/08/2012 Protocol reviewed at Haematology Reference Committee meeting.

Next review in 2 years.
19/06/2013 Added new bisphosphonate and VTE clinical information block.
02/09/2013 Approved and published on eviQ (from RCM 2012).
13/03/2015

Protocol reviewed at Haematology Reference Committee meeting. The following updates were made:

  • Dexamethasone dosing changed to 40mg on day 1, 8, 15, 22 throughout treatment as per reference committee.
  • Notes section updated.
  • Toxicity data from 2014 Benboubker et al. 2014 paper added.
  • Calculator removed.

Next review in 2 years.
18/10/2015 Removed reference to 'I-AccessTM Program'.
31/05/2017

Transferred to new eviQ website. Version number change to v.4.
24/11/2017

Protocol reviewed at Haematology Reference Committee meeting:

  • Reference to the 'i-AccessTM program' added back into drug status.
  • Added to indications 'Patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation'.
  • Added to dose modifications dexamethasone and lenalidomide reduction for the frail and elderly.
  • Added FIRST trial to evidence.
  • Version number increased to v.5.
24/05/2019

Protocol reviewed at Haematology Reference Committee meeting:

  • Note regarding dexamethasone updated.
  • Review in 2 years.
10/10/2019 Clinical information updated with PBS expanded indications for G-CSF. 
30/04/2021

Protocol reviewed at Haematology Reference Committee meeting. The following updates were made:

  • Late onset diarrhoea block added in side effects
  • Administration section updated to include all days of treatment

Next review in 2 years.
29/11/2021 Interactions updated.
21/12/2021

Changed antiemetic clinical information block to minimal or low, to align with new categories. See ID 7: Prevention of anti-cancer therapy induced nausea and vomiting (AINV) v5.
20/01/2022 Interactions updated.

The information contained in this protocol is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to treatment. Any clinician (medical oncologist, haematologist, radiation oncologist, medical physicist, radiation therapist, pharmacist or nurse) seeking to apply or consult this protocol is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information sources. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au

Send feedback for this page

First approved:
Last reviewed:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/547

10 May 2025